[11C]-NOP46 for Chronic Pain

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Chronic Pain[11C]-NOP46 - Drug
Eligibility
18 - 90
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a new radioactive chemical may help doctors better understand how the brain works.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 48 hours post-scan

48 hours post-scan
Occurrence of Physiologic Effects of Single Micro-dose of [11C]-NOP46
Uptake ratio for site with pain is >1

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Individuals with Focal Pain
1 of 2
Healthy Volunteers
1 of 2

Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: [11C]-NOP46 · No Placebo Group · Phase < 1

Individuals with Focal PainExperimental Group · 2 Interventions: PET/CT scan, [11C]-NOP46 · Intervention Types: Radiation, Drug
Healthy VolunteersExperimental Group · 2 Interventions: PET/CT scan, [11C]-NOP46 · Intervention Types: Radiation, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT scan
2013
Completed Phase 1
~340

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 hours post-scan

Who is running the clinical trial?

Akiva MintzLead Sponsor
Akiva Mintz, MD, PhDPrincipal Investigator - Columbia University
Columbia University

Eligibility Criteria

Age 18 - 90 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: